Invivyd, Inc. (IVVD) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Invivyd reported revenue of $53.4M, up 110.5% from $25.4M the year before. Net income was -$52.5M (a -98.2% net margin), or -$0.30 per diluted share. Operating margin was -104.0%. Operating activities generated -$58.1M of cash, leaving -$58.3M of free cash flow. At fiscal year end, Invivyd held $276.9M in total assets against $35.3M in total liabilities, including $226.7M of cash and equivalents.
Open the full interactive Invivyd financials → Quarterly statements, key ratios, valuation history and price charts.
Invivyd Key Stats
| Share Price | $0.65 |
|---|---|
| Market Cap | $207.0M |
| Revenue YoY Growth | +110.5% |
| 52-Week Range | $0.54 – $2.88 |
| Shares Outstanding | 320.4 million (basic, 2026 Q2) |
Invivyd Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $25.4M | $53.4M |
| Operating Income | -$226.9M | -$248.0M | -$212.8M | -$176.9M | -$55.6M |
| Pre-Tax Income | -$226.8M | -$241.3M | -$198.6M | -$169.9M | -$52.5M |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$226.8M | -$241.3M | -$198.6M | -$169.9M | -$52.5M |
| Diluted EPS | -$5.32 | -$2.23 | -$1.81 | -$1.43 | -$0.30 |
Invivyd Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $13.1M | $17.2M | $13.7M | $14.3M |
| Net Income | -$10.5M | -$11.1M | -$41.4M | -$44.4M |
| Diluted EPS | -$0.06 | -$0.06 | -$0.13 | -$0.14 |
Invivyd Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $542.2M | $92.1M | $200.6M | $69.3M | $226.7M |
| Current Assets | $616.7M | $376.9M | $224.9M | $100.7M | $247.5M |
| Total Assets | $620.1M | $383.2M | $229.2M | $129.5M | $276.9M |
| Current Liabilities | $62.1M | $25.0M | $50.3M | $62.0M | $34.2M |
| Total Liabilities | $62.1M | $27.2M | $51.7M | $62.0M | $35.3M |
| Shareholders' Equity | $558.0M | $356.0M | $177.5M | $67.5M | $241.5M |
Invivyd Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$184.7M | -$220.0M | -$173.2M | -$170.5M | -$58.1M |
| Cash From Investing | -$50.7M | -$230.7M | $280.7M | -$140,000 | -$155,000 |
| Cash From Financing | $662.7M | $506,000 | $1.0M | $39.3M | $215.6M |
| Free Cash Flow | -$184.8M | -$221.7M | -$173.8M | -$170.6M | -$58.3M |
Figures from Invivyd's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Invivyd financials page for every line item.
Invivyd Company Profile
| Ticker | IVVD |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | New Haven, Connecticut |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001832038 |
Frequently Asked Questions
What was Invivyd's revenue in fiscal 2025?
Invivyd (IVVD) reported revenue of $53.4M for fiscal 2025.
What is Invivyd's annual revenue history?
Invivyd's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $25.4M; 2025: $53.4M.
What was Invivyd's net income in fiscal 2025?
Invivyd reported net income of -$52.5M for fiscal 2025.
What was Invivyd's earnings per share (EPS) in fiscal 2025?
Invivyd's diluted EPS was -$0.30 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Invivyd generate in fiscal 2025?
Invivyd generated -$58.3M of free cash flow in fiscal 2025.
What was Invivyd's revenue last quarter?
In its most recent reported quarter (2026 Q2), Invivyd reported revenue of $14.3M.
How many shares of Invivyd are outstanding?
Invivyd reported a weighted average of 320.4 million basic shares outstanding in 2026 Q2.
What is Invivyd's market cap?
Based on its latest closing price, Invivyd (IVVD) has a market capitalization of about $207.0M.
When does Invivyd's fiscal year end?
Invivyd's fiscal year end, as registered with the SEC, is December 31.
Where is Invivyd headquartered?
Invivyd lists its business address in New Haven, Connecticut in its SEC filings.
Invivyd Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →